Investor's Business Daily (IBD) recently published a diatribe against 340B hospitals and the 340B program by Sally C. Pipes, who heads the "think tank" Pacific Research Institute. Among other fulminations, Pipes said 340B is an "ungainly operation fattening the bottom lines of pharmacies and hospitals," "fails to actually help vulnerable patients," and "represents an … [Read more...]
JAMA Publishes Letters Disputing Opinion Piece on 340B
Last May, the Journal of the American Medical Association (JAMA) published an article in its Viewpoint section by two academics (one of whom receives speaking fees from Genentech) stating that the 340B program raises costs for patients, particularly those with cancer. We're pleased to report that JAMA's Oct. 16 edition includes a letter to the editor from SNHPA pointing out … [Read more...]
Fla. Newspaper Publishes Response to Anti-340B Commentary
In late August, the South Florida Sun Sentinel published an op-ed lambasting the 340B program by Peter Pitts of the innocuous sounding Center for Medicine in the Public Interest. The commentary neglected to mention that "center" is heavily financed by drug companies and that Pitts himself has spent a good amount of his career as a PR executive for the drug industry. Pitts' … [Read more...]
The Many Ways 340B Is Making a Positive Difference
Setting the record straight about 340B involves more than just responding to the program's critics and pointing out where they’ve bent the truth or worse. Setting the record straight also means telling the story of how safety net hospitals and other caregivers use their 340B savings to meet the program's purpose of stretching scarce federal resources, serving more patients, and … [Read more...]
Genentech Overcharges Underscores Need For HRSA Action
Genentech, the biotech giant leading the charge for drug manufacturer audits of 340B safety net health care providers, admitted yesterday that it overcharged those caregivers for a big chunk of its entire product line from the middle of 2008 through the middle of 2011. The California-based company's Swiss owner, F. Hoffmann-La Roche AG, racked up 9.54 billion Swiss francs in … [Read more...]
Our Response to the Drug Industry 340B White Paper
We recently released a comprehensive 27-page report that corrects misunderstandings about the 340B drug discount program promoted by the pharmaceutical industry. That report addresses misconceptions and unfounded accusations of the program. It also calls for a number of ways to modernize the 340B program. Now, as a follow-up, we are focusing narrowly on the unfounded … [Read more...]
Setting the Record Straight on 340B: A Response to Critics
A new, comprehensive report released today corrects misinformation about a federal drug discount program and underscores how the program benefits vulnerable patients, including those with little or no ability to pay. Click here for the complete 27-page report. The report finds that the 340B drug pricing program continues to meet Congress’ intent of “enabling safety net … [Read more...]